- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01339897
A Safety Study Evaluating N6022 in Multiple-Ascending Doses in Healthy Subjects
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study Evaluating the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of N6022 in Healthy Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a double-blind, randomized, placebo-controlled, multiple ascending dose study, in at least three ascending cohorts. Twenty-four subjects will be enrolled initially in the first three cohorts, with up to 40 subjects to be enrolled overall if additional cohorts are required to reach the maximum tolerated dose (MTD). The cohorts will be enrolled in two groups of 4 each with approximately 7 days between groups to conduct safety monitoring committee review for approval to proceed to the second group in the cohort. Eight subjects will be enrolled per cohort, randomized 3:1 to N6022: placebo. Each subject will undergo screening (Day -28 to Day -2) and, if eligible, they will be instructed to begin a low-nitrate diet on Day -4. Subjects will return to the clinical site on Day -1, and eligibility will be reconfirmed. Eligible subjects will receive a dose of investigational medicinal product ([IMP], N6022 or placebo) by intravenous (IV) infusion on study Days 1 through 7 and will be followed for safety, PK, and PD until discharge on the morning of Day 8. Subjects will return to the clinic for a follow-up visit on Day 15 (± 1 day) and will be contacted via telephone on Day 28 (± 1 day) for the end-of-study safety follow-up visit. Participation of an individual subject may last approximately 56 days from the time of screening until the end-of-study follow-up visit.
A Safety Monitoring Committee (SMC) will review the safety data in each cohort after the Day 15 Follow-up visit, before proceeding to the next ascending dose cohort, modifying the dose, repeating a dose, or stopping the study according to the stopping rules outlined in the protocol.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21225
- PAREXEL International
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject is healthy, determined by pre-study medical evaluation (medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory evaluations
- Subject is a non-smoker (or other nicotine user) as determined by history (no nicotine use over the past year) and a negative urine cotinine test at screening and Day 1.
- Subject has a body weight > 50 kg and BMI between 19.5 and 29.5 kg/m2, inclusive, at screening.
- Subject has systolic BP > 90 mmHg and diastolic BP > 50 mmHg at screening or Day-1.
Exclusion Criteria:
- Subject has clinically significant history or evidence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, immunological, or psychiatric disorder(s) as determined by the investigator or designee.
- Subject is a current alcohol abuser and/or has a history of illicit drug abuse within six months of entry.
- Subject has donated blood (> 500 mL) or blood products within 56 days prior to Day -1.
- Subject has a history of bleeding disorders (i.e., severe hemorrhage, melena, rectal bleeding, nosebleeds, bruising, etc.).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 5 mg/N6022
Injectable formulation, given at doses per cohort of 5 mg given QD each day over 7 days.
|
Intravenous formulation, given at doses of 5 mg once each day over 7 days.
Other Names:
|
Placebo Comparator: Placebo
Injectable formulation normal saline
|
Same administration procedures as active
Other Names:
|
Active Comparator: 10mg/N6022
Injectable formulation, given at doses of 10 mg given QD each day over 7 days.
|
Intravenous formulation given at doses of 10 mg once each day over 7 days.
Other Names:
|
Active Comparator: 20mg/N6022
Injectable formulation, given at doses per cohort of 20 mg given QD each day over 7 days.
|
Intravenous formulation given at doses of 20 mg once each day over 7 days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of Escalating Multiple Doses of N6022 in Healthy Subjects
Time Frame: Over 7 days
|
Safety variables (adverse events, vital signs, physical examination, telemetry, 12-lead ECG, infusion site reactions, O2 saturation, and clinical laboratory assessments)
|
Over 7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics of N6022
Time Frame: Day 1, 24 hours
|
N6022 AUC0-tau measurements from Day 1
|
Day 1, 24 hours
|
Pharmacokinetics of N6022 Over 7 Days
Time Frame: Day 7, 24 hours
|
Analysis of N6022 AUC0-tau values from Study Day 7
|
Day 7, 24 hours
|
Pharmacokinetics of N6022 on Study Day 1
Time Frame: Day 1, 24 hours
|
Analysis of N6022 Cmax values on Study Day 1
|
Day 1, 24 hours
|
Pharmacokinetics of N6022 Cmax Values on Study Day 7
Time Frame: Day 7, 24 hours
|
Pharmacokinetic Analysis of N6022 Cmax values on Study Day 7
|
Day 7, 24 hours
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ronald Goldwater, MDCM, MSc(A), Parexel
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- N6022-1H1-03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on 5 mg/N6022
-
Nivalis Therapeutics, Inc.Completed
-
Nivalis Therapeutics, Inc.Completed
-
Nivalis Therapeutics, Inc.Completed
-
PfizerCompleted
-
Anesiva, Inc.CompletedTotal Knee Arthroplasty (Replacement)United States
-
Shandong Suncadia Medicine Co., Ltd.Not yet recruiting
-
GlaxoSmithKlineTerminated
-
Suzhou Kintor Pharmaceutical Inc,Completed
-
Janssen Research & Development, LLCTerminatedAsymptomatic Amyloid-positiveUnited States, Canada, United Kingdom, Belgium, Germany, Spain, Japan, Australia, Netherlands, Denmark, Mexico, Finland, Sweden
-
Proteimax Biotechnology Israel LTDRecruitingQuality of Life | Obesity | Sleep QualityUnited States